Marten Vos Email & Phone Number

Melbourne, Victoria, Australia

Key member of the Medicines Development for Global Health CMC operations team, responsible for the development and implementation of CMC strategies for Medicines Development for Global Health products, spanning early development through to product registration.

Auckland, New Zealand

Providing CMC, Chemistry, Technical, Product and Process Development advice and expertise to Pharmaceutical (Human & Veterinary), Chemical, Nutraceutical, Dairy and Food Industries.

Auckland, New Zealand

Responsible for all R&D functions in this startup company focused on cannabis based therapeutics.Key Accomplishments:◾ First regulatory approval and launch of a New Zealand made cannabidiol product under the NZ Medicinal Cannabis Regulations 2019.◾ Implemented a Stage-Gate process to manage and prioritise the R&D portfolio.◾ Proposed to separate R&D from.

Auckland, New Zealand

Continuation of previous role with Bayer Animal Health upon completion of the sale to Elanco Animal Health. Responsible for all pharmaceutical development (CMC & Regulatory), product / technology transfers to manufacturing and lifecycle management activities of commercial product for the Asia Pacific region.Key Accomplishments:◾ Successful integration of.

Auckland, New Zealand

Responsible for all pharmaceutical development (CMC & Regulatory), product / technology transfers to manufacturing and lifecycle management activities of commercial product for the Asia Pacific region. Hired to manage the transition of the Bayer Animal Health APAC Pharmaceutical Development team into the Elanco company structure as part of the sale to.

Auckland, New Zealand

Responsible for all pharmaceutical development (CMC development, regulatory support and technology transfer into manufacturing) at the NZ and USA sites. Managed a team of 36 research scientists responsible for technical development of an R&D project portfolio with a NPV> 200MM USD. Promoted from my previous role as Formulation Development Manager this role.

Auckland, New Zealand

Responsible for all formulation development at the NZ site. Managed a team of 10 formulation scientists responsible for dosage form and process development. Was asked by senior management to return to pharmaceutical R&D to take up the role of Formulation Development Manager in order to support the CSO and R&D director in building an R&D project portfolio.

Auckland, New Zealand

Responsible for all technical aspects and integration of the neutraceuticals business unit (Natural Health Laboratories Ltd) into the Douglas group in order to maintain regulatory compliance and provide technical support to sales, marketing and customers. Managed a team of 5 direct reports at head office in Auckland and a further 3 dotted line reports at.

Responsible for the technical aspects of new product development. Managed a small team of analytical and formulation scientists developing drug products and preparing CMC documentation to support regulatory submissions.Key Accomplishments:◾ First ANDA approval for Douglas by the US FDA.◾ EU approval for a line extension to a major Douglas export product.◾.

Groningen, Netherlands

Responsible for kilogram laboratory operations and scale up of synthetic organic chemistry routes for custom synthesis of complex novel molecules. Managed a team of four synthetic organic chemists (MSc / PhD) specialized in scale up from mg to kg quantities and redesign of synthetic routes to facilitate scale up of the synthesis of novel lead structures.

Groningen, Netherlands

Responsible for synthesis, route scouting and scale up of fine chemicals up to kilogram scale. Supervised two research chemists and oversaw general laboratory operations and maintenance. Reported to the founder.Key Accomplishments:◾ Promoted (6 months after hire) to supervise staff and oversee laboratory operations. ◾ Trained staff in scale up operations..

Groningen, Netherlands

Employed within the Positron Emission Tomography (PET) group of the department of Nuclear Medicine on a 2 year grant from the Dutch Digestive Foundation. The primary objective was to synthesize radioactively labelled molecules for imaging of tissue regeneration after liver transplants and automate the process the facilitate routine production.Key.

Groningen, Netherlands

Research period within the Positron Emission Tomography (PET) group (supervisors Professor P.H. Elsinga Ph.D. and G.M. Visser Ph.D.) of the department of Nuclear Medicine. The primary objective was the synthesis and in vivo evaluation of radioactively labelled [18F]-fluorocarazolol a ligand for the visualisation of pulmonary beta-adrenergic receptors with.

Postgraduate Courses

Engineer'S Degree

Education record